【摘要】 特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)是一种病因不明的慢性、进行性、纤维化性间质性肺炎,治愈率低而死亡率很高,目前有效的治疗药物较为匮乏。蛋白酶激活受体(protease activated receptors, PARs)的不可逆地激活对维持肺功能具有重要作用,PARs的异常表达与活化可促进炎症和纤维化过程。因此,在特发性肺纤维化的治疗中,靶向PARs可能成为一种新的治疗手段。该文介绍了PARs在促进特发性肺纤维化进程中的功能及作用机制,并且总结了靶向PARs的抗肺纤维化药物的研究进展。更多还原

【Abstract】 Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic interstitial pneumonia of unknown etiology. The cure rate is low and the mortality rate is high. At present, effective treatment drugs are scarce. Irreversible activation of PARs plays an important role in maintaining pulmonary function, and abnormal expression and activation of PARs can promote the process of inflammation and idiopathic pulmonary fibrosis. Therefore, targeted PARs may be a new therapeutic method in the treatment of idiopathic pulmonary fibrosis. This paper introduces the function and mechanism of PARs in promoting idiopathic pulmonary fibrosis, and summarizes the advance in anti-fibrosis drugs targeting PARs.更多还原